Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with chronic obstructive pulmonary disease (COPD) are at greater risk of suffering from diseases for which beta-blockers may be indicated and effective. Clinicians remain hesitant to administer beta-blockers to COPD patients for fear of adverse effects on lung function. However, cardioselective beta-blockers therapy led to a non-significant worsening of resting expiratory flow limitation measured by the forced expiratory volume in one second (FEV1) as compared to placebo. But, the FEV1 appears to be a crude estimate bronchial obstruction in COPD. Importantly, the effects of cardioselective beta-blockers on dynamic hyperinflation, a subtle marker of bronchial obstruction, remain unknown. Thus, a prospective placebo-controlled study assessing the effects of short-term cardioselective beta-blocker therapy on dynamic hyperinflation in patients with moderate-to-severe COPD is needed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laval University
• Treatments: Adrenergic beta-1 Receptor Antagonists; Bisoprolol

Criteria

Inclusion Criteria:

• age: >50 years old;

• cigarette exposure: >10 pack-year;

• moderate-to-severe COPD (Forced expiratory volume in one second/Forced vital capacity (FEV1/FVC) <70%; FEV1 between 30 to 80% predicted).

Exclusion Criteria:

• previous bronchospasm induced by beta-blockers;

• respiratory exacerbation in the previous 8 weeks;

• long-term oxygen therapy or arterial oxygen saturation <85% at rest;

• known coronary artery disease with persistent symptoms or persistent myocardial ischemia on cardiac imaging;

• left ventricular ejection fraction <40%;

• current treatment with oral corticosteroids;

• intrinsic musculoskeletal abnormality precluding exercise testing;

• medical condition for which the patient is currently treated with beta-blockers.